within Pharmacolibrary.Drugs.ATC.L;

model L01EB02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.59,
    Cl             = 7.45e-05,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.232,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011783333333333333,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.947,
    k12             = 13,
    k21             = 13
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Erlotinib is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is approved for use in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors and non-small cell lung cancer following oral administration.</p><h4>References</h4><ol><li><p>Karbownik, A, et al., &amp; Grześkowiak, E (2016). The alteration of pharmacokinetics of erlotinib and OSI420 in type 1 diabetic rabbits. <i>Pharmacological reports : PR</i> 68(5) 964–968. DOI:<a href=&quot;https://doi.org/10.1016/j.pharep.2016.04.015&quot;>10.1016/j.pharep.2016.04.015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27372922/&quot;>https://pubmed.ncbi.nlm.nih.gov/27372922</a></p></li><li><p>Reddick, SJ, et al., &amp; Stewart, CF (2019). Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. <i>Cancer chemotherapy and pharmacology</i> 84(4) 829–838. DOI:<a href=&quot;https://doi.org/10.1007/s00280-019-03921-3&quot;>10.1007/s00280-019-03921-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31392390/&quot;>https://pubmed.ncbi.nlm.nih.gov/31392390</a></p></li><li><p>Emoto-Yamamoto, Y, et al., &amp; Fukuoka, M (2015). Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer. <i>Journal of clinical pharmacy and therapeutics</i> 40(2) 232–239. DOI:<a href=&quot;https://doi.org/10.1111/jcpt.12232&quot;>10.1111/jcpt.12232</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25402940/&quot;>https://pubmed.ncbi.nlm.nih.gov/25402940</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EB02;
